Japan Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Japan · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$563.0 MnPlaceholder estimate
Estimate 2025$623.3 Mn6.9% of the global market
Projected 2034$1.56 Bn 149.6%Adds $932.7 Mn over 9 forecast years
CAGR 2025–203410.7%Faster than 63% of 180 Pharmaceuticals markets here
8 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Japan Radiopharmaceuticals Market Analysis Executive Summary
Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.
Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).
Japan Radiopharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Japan Radiopharmaceuticals Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.
Competitive Landscape for Radiopharmaceuticals Market in Japan
The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Radiopharmaceuticals Market in Japan
Radiopharmaceuticals in Japan: rules, payment and research
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] ClinicalTrials.gov lists 8 studies on Radiopharmaceuticals that are recruiting, active or about to start in Japan.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Isotope
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novartis
7.2 Bayer AG
7.3 Lantheus Holdings
7.4 Curium
7.5 Telix Pharmaceuticals
7.6 GE HealthCare
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The radiopharmaceuticals market can be segmented based on various criteria, including type, isotope and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Radiopharmaceuticals in context
Japan compared
Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Radiopharmaceuticals market in Japan?
Placeholder estimate: about $623.3 Mn in 2025, rising to about $1.56 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Radiopharmaceuticals market in Japan growing?
Placeholder estimate: about 10.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Radiopharmaceuticals market report cover?
The report splits the market by type (Diagnostic, Therapeutic), isotope (Lutetium-177, Actinium-225, Fluorine-18, Technetium-99m and more) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Radiopharmaceuticals market?
Key players include Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and GE Healthcare.
What is driving the Radiopharmaceuticals market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Who regulates Radiopharmaceuticals in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Radiopharmaceuticals are running in Japan?
8 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Radiopharmaceuticals?
PubMed lists 2,809 papers on Radiopharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Japan 
China
India
US
Canada
Germany
France
Brazil
UK
Italy
Ecuador
Spain
Mexico
Saudi Arabia
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
AstraZeneca
Eli Lilly and Company